Quest Diagnostics Inc. (NYSE: DGX) announced today its fourth‑quarter and full‑year 2025 financial results, reporting net revenues of $2.81 billion for the quarter and $11.04 billion for the year, up 7.1% and 11.8% respectively from 2024. The company posted diluted earnings per share of $2.42 for the quarter and $9.85 for the year, beating consensus estimates of $2.36 and $8.93 by 8.5% and 10.3%.
The company highlighted double‑digit growth in its Diagnostic Information Services segment, driven by strong demand from clinicians and health systems, and noted that operating income rose to $386 million, a 7.0% increase, reflecting effective cost controls and a favorable mix shift toward higher‑margin advanced diagnostics. Quest also reported a 15.3% operating margin for the year, up from 14.1% in 2024, underscoring its ability to expand profitability amid rising labor costs.
Quest Diagnostics raised its full‑year 2026 guidance, projecting net revenues of $11.70 billion to $11.82 billion, a 6.0%–7.1% increase, and diluted earnings per share of $9.45 to $9.65. The company reiterated its confidence in continued growth of its direct‑to‑consumer platform and the expansion of its Epic‑powered Project Nova, positioning it to capture additional market share in the increasingly consolidated laboratory services market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.